
    
      This study will use a double-blind, randomized, cross-over design with subjects serving as
      their own controls. This study will be conducted over a consecutive five-week period.

      All subjects will be asked to discontinue taking their short- and long-acting beta-agonist
      medication 12 and 24 hours respectively prior to data collection. Also, all subjects will be
      asked to refrain from caffeine, physical activity, and NSAID use 24 hours prior to testing.
      In addition all subjects will be asked to abstain from taking any vitamin supplement during
      the course of the study.
    
  